Immunotoxin Therapy of Cancer
Reads0
Chats0
TLDR
Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.Abstract:
Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.read more
Citations
More filters
Journal ArticleDOI
Nanocarriers as an emerging platform for cancer therapy
Dan Peer,Jeffrey M. Karp,Jeffrey M. Karp,Seungpyo Hong,Omid C. Farokhzad,Rimona Margalit,Robert Langer +6 more
TL;DR: The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.
Journal ArticleDOI
Paul Ehrlich's magic bullet concept: 100 years of progress.
Klaus Strebhardt,Axel Ullrich +1 more
TL;DR: The intellectual foundations of the development of cancer drug development are revisited, as many have shown great clinical success and are therefore appropriate to revisit.
Journal ArticleDOI
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers
Carlee E. Ashley,Carlee E. Ashley,Eric C. Carnes,Genevieve K Phillips,David Patrick Padilla,Paul N. Durfee,Page A. Brown,Tracey N. Hanna,Juewen Liu,Juewen Liu,Brandy Phillips,Mark B. Carter,Nick J. Carroll,Xingmao Jiang,Darren R. Dunphy,Cheryl L. Willman,Dimiter N. Petsev,Deborah G. Evans,Atul N. Parikh,Bryce Chackerian,Walker Wharton,David S. Peabody,C. Jeffrey Brinker +22 more
TL;DR: P porous nanoparticle-supported lipid bilayers (protocells) that synergistically combine properties of liposomes and nanoporous particles are reported that allow a single protocell loaded with a drug cocktail to kill a drug-resistant HCC cell, representing a 106-fold improvement over comparable liposome.
Journal ArticleDOI
Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
Makoto Mitsunaga,Mikako Ogawa,Nobuyuki Kosaka,Lauren T Rosenblum,Peter L. Choyke,Hisataka Kobayashi +5 more
TL;DR: A new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors is developed.
References
More filters
BookDOI
The Case Study
TL;DR: On May 25, 1977, IEEE member, Virginia Edgerton, a senior information scientist employed by the City of New York, telephoned the chairman of CSIT's Working Group on Ethics and Employment Practices, having been referred to the committee by IEEE Headquarters.
Journal Article
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.
Journal ArticleDOI
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
Jens Dannull,Zhen Su,David A. Rizzieri,Benjamin K. Yang,Doris Coleman,Donna Yancey,Aijing Zhang,Philipp Dahm,Nelson J. Chao,Eli Gilboa,Johannes Vieweg +10 more
TL;DR: It is shown that DAB(389)IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25.
Journal ArticleDOI
The IL -2 IL-2 receptor system: A current overview
TL;DR: The IL-2 system has been extensively studied in the context of the clonal proliferation of T cells and has become a paradigm of how interleukins and other soluble mediators, collectively termed cyto- kines, function in the development and regulation of the immune system.
Journal ArticleDOI
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
Kai Chang,Ira Pastan +1 more
TL;DR: Monoclonal antibody MAb K1 recognizes a 40-kDa glycoprotein present on the surface of mesothelial cells, mesotheliomas, and ovarian cancers, and this antigen was found on the cell surface and could be released by treatment with phosphatidylinositol-specific phospholipase C.